>>60537298
I'll let you in on a secret: this cashflow shit is a gigantic meme if it isn't some gigantic company's stock.

All the best biotech investments are microcaps hemorrhaging cash in the pre-revenue stage doing R&D, and I've tipped Martens off to a few. You value those kinds of companies based off of future expected revenue from their intellectual property, discounted by the probability of intervention approval.